Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

SAN FRANCISCO--(BUSINESS WIRE)--On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug ("erso†). The company has billed this drug as a potential treatment for hypoglycemia caused by hyperinsulinism ("HI†). The news, analyst moves, and severe market reaction have prompted national shareholders rights firm Hagens Berman to open an investiga ...